Birth control

Uniform Advantage Donates another $20,000 to the Breast Cancer Research Foundation

Saturday, September 25, 2021 - 5:00am

FORT LAUDERDALE, Fla., Sept. 25, 2021 /PRNewswire-PRWeb/ -- Uniform Advantage (UA), a multi-channel retailer of medical uniforms for medical and hospitality industries, continues its partnership with the Breast Cancer Research Foundation (BCRF) to raise funds for the advancement of breast cancer research.

Key Points: 
  • FORT LAUDERDALE, Fla., Sept. 25, 2021 /PRNewswire-PRWeb/ -- Uniform Advantage (UA), a multi-channel retailer of medical uniforms for medical and hospitality industries, continues its partnership with the Breast Cancer Research Foundation (BCRF) to raise funds for the advancement of breast cancer research.
  • "This year, breast cancer became the most commonly diagnosed cancer worldwide," said BCRF President and CEO Myra Biblowit.
  • By partnering with the highest-rated breast cancer organization the country, Uniform Advantage is enabling lifesaving research."
  • Founded in 1993 by Evelyn H. Lauder, the Breast Cancer Research Foundation is the largest private funder of breast cancer research in the world.

DKT International Publishes 2020 Contraceptive Social Marketing Statistics

Thursday, September 23, 2021 - 8:50pm

DKT International , one of the largest providers of sexual and reproductive health products and services in the developing world, is proud to announce the release of the 2020 Contraceptive Social Marketing Statistics report .

Key Points: 
  • DKT International , one of the largest providers of sexual and reproductive health products and services in the developing world, is proud to announce the release of the 2020 Contraceptive Social Marketing Statistics report .
  • According to the report, 112 programs produced 81.6 million Couple Years of Protection* (CYPs) in 68 countries in 2020.
  • Further sales highlights from the 2020 Contraceptive Social Marketing Statistics Report include:
    Since 1991, DKT International has published the report that highlights 112 contraceptive social marketing programs, all of which help provide modern contraception and reduce unmet need for family planning, largely through the private sector.
  • Since 1989, DKT Internationals core mission has been to provide safe and affordable options for family planning and HIV prevention through social marketing in underserved countries throughout Latin America, Africa, and Asia.

Advisory - BlackOxygen Organics recalls fulvic acid tablets and powder due to potential health risks

Thursday, September 23, 2021 - 8:55pm

Issue: BlackOxygen Organics is recalling all lots of these products due to potential health risks which may be higher for children, adolescents, and pregnant or breastfeeding women.

Key Points: 
  • Issue: BlackOxygen Organics is recalling all lots of these products due to potential health risks which may be higher for children, adolescents, and pregnant or breastfeeding women.
  • The products are being promoted in ways and for uses that have not been evaluated and authorized by Health Canada.
  • BlackOxygen Organcs is recalling all lots of BlackOxygen Tablets (NPN 80106662) and BlackOxygen Organics Powder (NPN 80097385) due to potential health risks.
  • These products are being marketed as fulvic acid supplement(s); however, this use and the quantity of fulvic acid provided by these products has not been evaluated or authorized by Health Canada.

DGAP-News: Abivax presents first-half 2021 financial results and operations update

Thursday, September 23, 2021 - 5:23pm

2021 Research Tax Credit revenue amounts to EUR 1.6M as of June 30, 2021.

Key Points: 
  • 2021 Research Tax Credit revenue amounts to EUR 1.6M as of June 30, 2021.
  • Cash at the end of June 2021 was EUR 4.3M, compared to EUR 29.3M at the end of 2020, before taking into account the EUR 85M financing realized in July 2021.
  • In March 2021, Abivax announced it would be stopping the phase 2b/3 Covid-19 study (miR-AGE trial - ABX464-401) due to lack of efficacy.
  • Abivax would like to thank him for his contribution and wishes him all the best in his future endeavors.

Ovarian CanceRx: New Innovative Clinical Research Effort Seeks to Accelerate the Development of New Treatments for Deadliest Gynecological Cancer

Thursday, September 23, 2021 - 4:30pm

Working in collaboration with key members of the research, clinical and patient advocacy communities, Ovarian CanceRx capitalizes on novel drug development to give ovarian cancer patients access to potentially beneficial treatments at a time when they need them most now!

Key Points: 
  • Working in collaboration with key members of the research, clinical and patient advocacy communities, Ovarian CanceRx capitalizes on novel drug development to give ovarian cancer patients access to potentially beneficial treatments at a time when they need them most now!
  • While there are numerous randomized control trials in ovarian cancer, there are still significant unmet clinical needs in this field.
  • A key stakeholder in the effort is Ovarian Cancer Research Alliance (OCRA), the worlds largest ovarian cancer charity.
  • Through GCARs Ovarian CanceRx partnership we are gratified to support an innovative clinical trial design that will improve treatment for women with ovarian cancer.

South Carolina Nonprofit Pioneers a New Approach to Birth Control Access

Thursday, September 23, 2021 - 3:30pm

It provides eight FDA-approved birth control methods for free or low- cost through a network of 119 clinical sites across the state.

Key Points: 
  • It provides eight FDA-approved birth control methods for free or low- cost through a network of 119 clinical sites across the state.
  • Today, every woman in South Carolina has an equal opportunity to obtain family planning counseling and whatever birth control method she chooses, no matter where she lives or her economic status.
  • "Access to birth control is directly tied to better health outcomes for our state's women, children and families.
  • Founded in 2002 with private funding, New Morning is a nonprofit organization that has spent its two decades advocating for equitable reproductive education and access to birth control throughout South Carolina.

Pear Therapeutics Announces Additional Coverage Decisions and Formulary Adoption of its Prescription Digital Therapeutics

Thursday, September 23, 2021 - 1:02pm

Pear Therapeutics, Inc. , the leader in developing and commercializing prescription digital therapeutics (PDTs) to treat serious disease, today updated the number of entities providing coverage for its three commercial products, reSET, reSET-O, and Somryst.

Key Points: 
  • Pear Therapeutics, Inc. , the leader in developing and commercializing prescription digital therapeutics (PDTs) to treat serious disease, today updated the number of entities providing coverage for its three commercial products, reSET, reSET-O, and Somryst.
  • We thank our new covering entities for their leadership in embracing prescription digital therapeutics for their members and their families, said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics.
  • Pear recently released publications showing the potential for improved health outcomes and decreased treatment costs for patients using reSET-O5-11.
  • Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs.

7 Ways Women Can Take Charge of Their Sexual Health Right Now

Thursday, September 23, 2021 - 2:35pm

Its not just a nice thing to do, but a must do for women to be in touch with their own bodies and sexual health, says Dr. Minkin.

Key Points: 
  • Its not just a nice thing to do, but a must do for women to be in touch with their own bodies and sexual health, says Dr. Minkin.
  • The more questions answered by a trusted source, the more confident you can feel addressing issues when they arise and take control of your health, both physically and mentally.
  • If you think you might have a hormone imbalance, its best to get tested now and find solutions for your overall health.
  • Communication is key to the happiness of you and your partner and to the health of your relationship.

Corporate Accountability Action Launches #OfftheBANWagon Campaign To Hold Financial Backers of Texas Abortion Ban Accountable

Thursday, September 23, 2021 - 2:15pm

The new project will shine a light on the corporations that have bankrolled the campaigns of the Texas state legislators who sponsored this cruel abortion ban.

Key Points: 
  • The new project will shine a light on the corporations that have bankrolled the campaigns of the Texas state legislators who sponsored this cruel abortion ban.
  • As a result of the Texas ban, state legislatures across the country are considering extreme abortion ban laws of their own, taking away long-established reproductive rights.
  • The #OffTheBANWagon campaign, a project of Corporate Accountability Action and American Bridge 21st Century, will be releasing advertisements focused on educating Texas residents on the corporate backers of the ban, along with the critical role these major corporations played in the ultimate passing of the law.
  • To learn more about how to hold these corporations accountable, visit OffTheBANWagon.org or Twitter @CAAction2021 , Facebook at / corporateaccountabilityaction , or on Instagram @corporateaccountabilityaction .

Fortini™ Infant Formula Clears FDA Review; Energy- and Nutrient-dense Formula Aims to Set New Standard in U.S. to Support Growth in Infants with, or at Risk of, Failure to Thrive

Thursday, September 23, 2021 - 1:35pm

It is the first and only 30 kcal/fl oz formula in the U.S. that is nutritionally complete, ready-to-feed and specifically calibrated for term infants with undernutrition or failure to thrive.

Key Points: 
  • It is the first and only 30 kcal/fl oz formula in the U.S. that is nutritionally complete, ready-to-feed and specifically calibrated for term infants with undernutrition or failure to thrive.
  • All formulas marketed in the United States must meet federal nutritional, growth and safety requirements, and infant formula manufacturers must notify the FDA prior to marketing a new formula.
  • Fortini has been shown in clinical trials to be well tolerated and supports weight gain and catch-up growth in failure-to-thrive infants under medical supervision.
  • Until now, there has been no such formula available in the U.S. for term infants with failure to thrive or growth failure.